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RESEARCH ARTICLE
111In-Trastuzumab Scintigraphy in HER2-Positive
Metastatic Breast Cancer Patients Remains Feasible during
Trastuzumab Treatment
Sietske B.M. Gaykema,* Johan R. de Jong,* Patrick J. Perik, Adrienne H. Brouwers, Carolien P. Schro¨der,
Thijs H. Oude Munnink, Alphons H.H. Bongaerts, Elisabeth G.E. de Vries, and Marjolijn N. Lub-de Hooge
Abstract
Human epidermal growth factor receptor (HER)2 imaging with radiolabeled trastuzumab might support HER2-targeted therapy. It is,
however, frequently questionedwhether HER2 imaging is also possible during trastuzumab treatment as the receptormight be saturated.
We studied the effect of trastuzumab treatment on 111In-trastuzumab uptake. Patients received trastuzumab weekly and paclitaxel
once every 3weeks. 111In-trastuzumabwas injected on day 1 of cycle 1 and day 15 of cycle 4.Whole-body planar scintigraphywas acquired
at different time points postinjection. Tumor uptake and organ distribution between the first and repeated scan serieswere calculated via
residence times. Twenty-five tumor lesions in 12 patients were visualized on both scintigraphy series. Tumor uptake decreased (19.6%;
p 5 .03). The residence times of normal organs remained similar except for the cardiac blood pool (+ 16.3%; p 5 .014). Trastuzumab
treatment decreases tumor 111In-trastuzumab uptake around 20%. HER2 imaging is feasible during trastuzumab treatment.
T UMOR OVEREXPRESSION or amplification of thehuman epidermal growth factor receptor (HER)2
occurs in 25 to 30% of patients with breast cancer. It is
involved in tumor cell survival, proliferation, maturation,
dissemination, and angiogenesis and has antiapoptotic
effects.1,2 Trastuzumab is a humanized monoclonal antibody
approved for treatment in the (neo)adjuvant and metastatic
setting of patients with HER2-positive breast cancer. The
addition of trastuzumab to chemotherapy results in an
increased time to disease progression, higher objective
response rates, and longer overall survival.3,4 Accurate
characterization of HER2 expression is essential for optimal
therapy. Therefore, HER2 status should be assessed in all
patients with breast cancer to identify HER2-positive
tumors. Ex vivo methods to determine the HER2 status of
the primary tumor are immunohistochemistry (IHC) and
fluorescence in situ hybridization (FISH). These methods
require biopsies, which are not always feasible. Furthermore,
sampling error cannot be ruled out with repeated biopsies.
This is particularly relevant in view of possible hetero-
geneous HER2 expression. Heterogeneity can exist between
the primary tumor and the metastases,5 between different
metastases, and within a metastasis. Discordance of HER2
expression between primary tumors and metastases, as
measured by IHC and/or FISH, varies between 10 and
24%.6,7 Loss or gain of HER2 expression can have clear
therapeutic consequences as patients with HER2-positive
lesions benefit from anti-HER2 therapy.3,8 This underlines
the necessity to accurately assess HER2 status during the
course of metastatic breast cancer. Noninvasive determina-
tion of HER2 expression can potentially be performed with
molecular imaging. This might facilitate selection of patients
for HER2-targeted therapy and assess the immediate
response to therapeutic interventions. In the clinical setting,
HER2 imaging may be performed with trastuzumab
radiolabeled with the c-emitter indium 111 (111In) and with
the positron emission tomography (PET) isotope zirconium
89 (89Zr).9,10 Experience with HER2 imaging increases;
however, this comes with the frequently asked questions as
to whether and how trastuzumab treatment affects the HER2
scan as the receptor may be already occupied. We previously
reported about 111In-trastuzumab scintigraphy in 17 patients
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with HER2-overexpressing metastatic breast cancer after the
first loading dose of trastuzumab.9 Some of these patients
underwent a second scintigraphy procedure during treatment.
This gives us the unique opportunity to assess the feasibility of
HER2 imaging in patients while on trastuzumab treatment.
Therefore, the aim of this study was to quantitatively describe
the biodistribution and uptake of 111In-trastuzumab over
time during 12 weeks of trastuzumab treatment.
Methods
Patients and Treatment
Eligibility criteria were described earlier.9 In short, patients
were women with histologically confirmed HER2-positive
metastatic breast cancer eligible for treatment with pacli-
taxel and trastuzumab. After the loading dose of 4 mg/kg,
trastuzumab was administered as a weekly intravenous
infusion of 2 mg/kg. Paclitaxel (175 mg/m2) was adminis-
tered intravenously in 4 hours as an intravenous infusion,
once every 3 weeks for six cycles. The study was approved by
the local medical ethical committee. All patients provided
written informed consent.
111In-Trastuzumab Scintigraphy
Trastuzumab was radiolabeled with 111In, as previously
described.11 A total of 100 to 150 MBq of 5 mg 111In-
trastuzumab was injected intravenously within 24 hours
after the infusion of the trastuzumab loading dose at
baseline. 111In-trastuzumab injection was repeated after the
trastuzumab dose on day 15 of the fourth cycle (14 weeks
later). Whole-body planar scintigraphy was performed at
four different time points at 15 minutes and 24, 72 to 96,
and 168 hours postinjection (Figure 1). A dual-head
Multispect-2 camera or dual-head E.Cam camera was used
(Siemens, CTI, Knoxville, TN) as previously described.9
Scintigraphy series for each patient series were performed
on the same camera. Only patients with a first and a
repeated scintigraphy series were analyzed. For quality
control of dosimetry calculations, an aliquot of dose
containing a known fraction of the injected radioactivity
was positioned adjacent to the patient during scanning.
111In-Trastuzumab Tumor Uptake, Organ
Distribution, and Radiation Dosimetry
The uptake of 111In-trastuzumab was determined by
calculating residence times for tumors and organs.
Residence time was defined as the area under the curve of
radioactivity versus time (time-activity curve) and was
calculated using the SPRIND (Radboud University Medical
Center, Nijmegen, The Netherlands) software package.12 The
set of organs for which the residence times were calculated
was limited to those organs that were clearly distinguishable
on planar scintigraphy. Also, the residence time was used for
internal radiation dose assessment according to the medical
internal radiation dose (MIRD) scheme.13 The radiation
absorbed dose for all organs of interest and the effective
dose were determined in accordance with International
Commission on Radiological Protection Publication 60
(ICRP 60).14 The estimated dose (ED) was calculated as a
weighted mean of the absorbed radiation dose over organs
defined within the ICRP framework. Organ-level internal
radiation dose calculations using the MIRD and ICRP 60 are
implemented in the OLINDA/EXM (Vanderbilt University,
Nashville, TN) software package.15 OLINDA/EXM incorpo-
rates a set of phantoms (e.g., adult male, adult female) that
define the size of organs and the geometric relation between
them. This determines the contribution from radioactivity
in one organ to the absorbed dose in another organ. The
quantitative results of the scintigraphy series were statisti-
cally tested for difference between the first and repeated
scintigraphy series.
Statistical Analysis
Data are presented as mean 6 standard deviation.
Statistical analysis was performed using the Wilcoxon test
for paired nonparametric data (SPSS version 19, IBM,




Seventeen patients were included between January 2002 and
June 2004. In 12 patients, serial analyses of tumor uptake,
organ absorbed dose, and radiation dosimetry, determined
from 111In-trastuzumab scintigraphy on first and second
scintigraphy series, could be assessed. Of the remaining five
patients, three were withdrawn from the study prematurely
due to clinical deterioration and/or disease progression, and
in two patients, the scintigraphy series were incomplete.
111In-Trastuzumab Tumor Uptake
In these 12 patients, 25 tumor lesions in total were
detected on 111In-trastuzumab scintigraphy at the first and
2 Gaykema et al
repeated scintigraphy series during treatment (see Figure 2
for an example). In 20 of the 25 tumor lesions, the 111In-
trastuzumab uptake was decreased at the repeated
compared to the first scintigraphy series. The mean
residence time in tumor lesions was 0.22 6 0.30 hours
(range 0.04–1.26 hours) at baseline and 0.14 6 0.17 hours
(range 0.02–0.79 hours) after 12 weekly therapeutic
trastuzumab doses. Between the first and the repeated
scintigraphy series, there was a mean reduction in 111In-
trastuzumab uptake per lesion of 19.6% 6 53.8 (range
increase of 72.9% to a decrease of 188.5%; p 5 .003). The
mean reduction per patient was 17.0% 6 35.0 (p 5 .07).
In the imaging time series, the tumor to background ratio
increased from the earliest time point up to the latest time
point (168 hours). Also, the visibility of the lesions
continued to increase at later time points. Within the time
scale of imaging in the present study, the limiting factor is
the radioactive decay, which causes an increase in noise in
the images over time. Up to 72 hours, blood vessels are still
clearly visible, indicating relatively high plasma levels
of trastuzumab. For imaging or uptake assessment, a
minimum time of 96 hours (4 days) between tracer
injection and imaging is recommended.
111In-Trastuzumab Organ Distribution and Radiation
Dosimetry
The residence times of healthy organs remained the same
between the first and the repeated scintigraphy series,
except for an increase in the cardiac blood pool (p 5 .014)
(Table 1). The absorbed dose for the organs and the
effective dose thus also remained similar. The effective
dose of 111In-trastuzumab was 0.19 6 0.02 mSv/MBq. The
three organs with the highest absorbed dose were liver (0.60
6 0.18 mGy/MBq), spleen (0.36 6 0.08 mGy/MBq), and
heart wall (0.34 6 0.05 mGy/MBq). The three organs with
Figure 1. 111In-trastuzumab scinti-
graphy at 24, 72, 96, and 168 hours
postinjection in the first (A) and
repeated (C) scan series. The pleural
lesion on computed tomography
(indicated with an arrow) pretreat-
ment (B) is almost completely dis-
appeared after treatment (D).
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the highest contribution to the effective dose were liver
(0.030 6 0.009 mSv/MBq), lungs (0.035 6 0.007/mSv MBq),
and ovaries (0.032 6 0.004 mSv/MBq) (Table 2).
Discussion and Conclusions
This is the first study with serial 111In-trastuzumab
scintigraphy at the start and during trastuzumab treatment
in patients with HER2-positive metastatic breast cancer. It
showed persistent 111In-trastuzumab uptake in all tumor
lesions during trastuzumab treatment, with only a 20%
lower absolute uptake after 12 weeks of trastuzumab
treatment. This indicates that sufficient HER2 is constantly
available at the tumor cell membrane to bind trastuzumab
and that it is impossible to completely saturate the
receptor. Furthermore, this is the first study to present
radiation dosimetry data for 111In-trastuzumab.
There are several potential explanations contributing to
the 19.6% lower 111In-trastuzumab uptake during trastu-
zumab treatment. It may be the consequence of the
antitumor effect of paclitaxel and trastuzumab on the size
of the tumor lesion or on HER2 expression itself.
Unfortunately, rigorous evaluation of size effects of all
tumor lesions was not possible. A feature of metastatic
breast cancer is that, very frequently, metastases are located
in the bones. This makes them most often not accessible
for official analyses according to Response Evaluation
Criteria in Solid Tumors (RECIST). Also, no serial biopsies
were taken, so downregulation of HER2 expression could
not be assessed. The final important explanation for the
lower 111In-trastuzumab uptake during treatment might be
that therapeutic trastuzumab circulating in the blood
competes with 111In-trastuzumab for binding to HER2. Of
the normal organs, only the cardiac blood pool showed a
16% higher uptake of 111In-trastuzumab after the second
injection during treatment. This can be explained by the
fact that the trastuzumab elimination half-life is dose
dependent; after multiple trastuzumab doses, half-life time
increases.16 However, we showed that tumor lesions could
still be clearly visualized under trastuzumab treatment.
Thus, we conclude that there is no complete down-
regulation or saturation of the HER2. Preferably, this
would be confirmed with HER2 staining of tumor tissue in
future clinical studies.
The disadvantage of biopsies is that there is only
information on a small piece of a metastasis, although the
tumor and its metastases can be heterogeneous.5 However,
Figure 2. 111In-trastuzumab scinti-
graphy in a patient with multiple
bone lesions in the right humerus,
and left os ilium (iliac crest and
adjacent to sacroiliac joint) (arrows)
at the first and repeated scan series.
Table 1. Calculated Residence Times with Standard Deviations of




Blood pool 2.39 6 0.71 2.78 6 0.71
Kidney 0.86 6 0.30 0.86 6 0.31
Liver 12.96 6 5.15 11.13 6 4.29
Lung 3.26 6 1.09 3.36 6 1.25
Spleen 0.91 6 0.33 0.92 6 0.27
Red marrow 0.78 6 0.19 0.90 6 0.22
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preclinical data are available. Preclinical evaluation of
change of HER2 status on trastuzumab therapy with
molecular imaging was performed previously in two
studies with a human breast cancer xenograft. Micro–
single-photon emission computed tomography (SPECT)
with 111In-pertuzumab and 18F-FBEM-HER2:243 was per-
formed pre- and posttrastuzumab treatment in mice
bearing human tumor xenografts. Uptake of the tracers
was decreased, but not completely blocked, after 3 weeks of
treatment, which corresponded with changes in tumor
size.17,18 Distinct from our study, there was no competi-
tion between the tracer and the therapeutic agent in these
studies because both tracers bind to another domain of
HER2 than trastuzumab. Thus, extrapolating to our study
results, we conclude that during trastuzumab treatment,
visualization of tumor lesions with 111In-trastuzumab is
feasible and not completely blocked or saturated, despite
this competition of the (subtherapeutic amount of)
radiolabeled trastuzumab with therapeutic trastuzumab.
In a human HER2-overexpressing SKOV-3 ovarian tumor
xenograft, there was higher uptake of 111In-trastuzumab
compared to a HER2-negative tumor xenograft,11 indicating
tumor-specific uptake.
As no significant differences in organ distribution were
found, the radiation absorbed dose of organs between the
two scintigraphy series is comparable. Radiation dose
estimates with 111In-trastuzumab were comparable to
those calculated by others.19 Trastuzumab can also be
radiolabeled with the positron emission tomography
(PET) isotope copper 64 (NCT01093612) or zirconium
89 (89Zr) for clinical purposes. PET provides a higher spatial
resolution, a better signal to noise ratio, and better
quantification. No dosimetric results for 89Zr-trastuzumab
have been published so far. However, as the physical half-lives
of 111In and 89Zr are comparable, the data for 111In-
trastuzumab can be used to estimate the ED for 89Zr-
trastuzumab, resulting in an ED of 0.5 mSv/MBq 89Zr. For a
typical administration of 37 MBq of 89Zr-trastuzumab, the
radiation dose amounts to 18 mSv, which is comparable to
the radiation dose of 100 MBq 111In.
We realize that this study has several shortcomings,
mainly because it was originally not intended and powered to
Table 2. Radiation Absorbed Dose Estimates for Organs and Effective Dose Contribution of ICRP Publication 60 Target Organs on the
First Scan Series
Organ Radiation Absorbed Dose (mGy/MBq) 6 SD ICRP 60 Effective Dose Contribution (mSv/MBq) 6 SD
Adrenal gland 230 6 17 1.1 6 0.2
Brain 106 6 16 0.5 6 0.1
Breast 115 6 12 5.7 6 0.6
Gallbladder wall 277 6 37 *
Lower colon wall 152 6 21 18.3 6 2.6
Small intestine 156 6 16 0.7 6 0.1
Stomach wall 181 6 16 21.8 6 1.9
Upper colon wall 180 6 15 0.9 6 0.2
Heart wall 339 6 49 *
Kidney 268 6 42 1.3 6 0.3
Liver 598 6 183 29.9 6 9.1
Lung 291 6 54 34.9 6 6.5
Muscle 131 6 14 0.6 6 0.1
Ovary 158 6 21 31.7 6 4.1
Pancreas 238 6 17 1.1 6 0.2
Red marrow 132 6 15 15.8 6 1.8
Skin 84 6 10 0.8 6 0.1
Spleen 360 6 78 2.8 6 3.2
Thymus 167 6 21 0.8 6 0.2
Thyroid 117 6 17 5.8 6 0.8
Urinary bladder wall 140 6 20 7.0 6 1.0
Uterus 156 6 21 0.7 6 0.1
Total body 151 6 13 *
Effective dose * 185 6 16
*Not defined.
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look at tumor size and HER2 expression over time. However,
although experience with molecular HER2 imaging is
expanding, we wondered whether trastuzumab treatment
affects imaging. The fact that this study showed that all tumor
lesions remained visible during treatment means that HER2
imaging is feasible even during trastuzumab treatment.
Acknowledgment
Financial disclosure of authors: This work was supported by
grants RUG 2007-3739 and RUG 2009-4273 from the Dutch
Cancer Society.
Financial disclosure of reviewers: None reported.
References
1. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer:
correlation of relapse and survival with amplification of the HER-
2/neu oncogene. Science 1987;235:177–82, doi:10.1126/science.
3798106.
2. Masood S, Bui MM. Prognostic and predictive value of HER2/neu
oncogene in breast cancer. Microsc Res Tech 2002;59:102–8,
doi:10.1002/jemt.10181.
3. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy
plus a monoclonal antibody against HER2 for metastatic breast
cancer that overexpresses HER2. N Engl J Med 2001;344:783–92,
doi:10.1056/NEJM200103153441101.
4. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of
the efficacy and safety of humanized anti-HER2 monoclonal
antibody in women who have HER2-overexpressing metastatic
breast cancer that has progressed after chemotherapy for metastatic
disease. J Clin Oncol 1999;17:2639–48.
5. Tanchiu E, Kaufman PA, Paik S, et al. registHER: a prospective,
longitudinal cohort study of women with HER2 positive metastatic
breast cancer [abstract]. J Clin Oncol 2005;23:670.
6. Niikura N, Liu J, Hayashi N, et al. Loss of human epidermal
growth factor receptor 2 (HER2) expression in metastatic sites of
HER2-overexpressing primary breast tumors. J Clin Oncol 2012;
30:593–9, doi:10.1200/JCO.2010.33.8889.
7. Amir E, Miller N, Geddie W, et al. Prospective study evaluating the
impact of tissue confirmation of metastatic disease in patients with
breast cancer. J Clin Oncol 2012;30:587–92, doi:10.1200/JCO.2010.
33.5232.
8. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al.
Trastuzumab after adjuvant chemotherapy in HER2-positive breast
cancer. N Engl J Med 2005;353:1659–72, doi:10.1056/NEJMoa
052306.
9. Perik PJ, Lub-De Hooge MN, Gietema JA, et al. Indium-111-
labeled trastuzumab scintigraphy in patients with human epider-
mal growth factor receptor 2-positive metastatic breast cancer.
J Clin Oncol 2006;24:2276–82, doi:10.1200/JCO.2005.03.8448.
10. Dijkers EC, Oude Munnink TH, Kosterink JG, et al.
Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-
positive lesions in patients with metastatic breast cancer. Clin
Pharmacol Ther 2010;87:586–92, doi:10.1038/clpt.2010.12.
11. Lub-de Hooge MN, Kosterink JG, Perik PJ, et al. Preclinical
characterisation of 111In-DTPA-trastuzumab. Br J Pharmacol 2004;
143:99–106, doi:10.1038/sj.bjp.0705915.
12. Visser E, Postema E, Boerman O, et al. Software package for
integrated data processing for internal dose assessment in nuclear
medicine (SPRIND). Eur J Nucl Med Mol Imaging 2007;34:413–
21, doi:10.1007/s00259-006-0226-z.
13. Howell RW, Wessels BW, Loevinger R, et al. The MIRD
perspective 1999. Medical Internal Radiation Dose Committee.
J Nucl Med 1999;40:3S–10S.
14. 1990 recommendations of the International Commission on
Radiological Protection. Ann ICRP 1991;21:1–201.
15. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-
generation personal computer software for internal dose assess-
ment in nuclear medicine. J Nucl Med 2005;46:1023–7.
16. Bruno R, Washington CB, Lu JF, et al. Population pharmacoki-
netics of trastuzumab in patients with HER2+ metastatic breast
cancer. Cancer Chemother Pharmacol 2005;56:361–9, doi:10.1007/
s00280-005-1026-z.
17. McLarty K, Cornelissen B, Cai Z, et al. Micro-SPECT/CT
with 111In-DTPA-pertuzumab sensitively detects trastuzumab-
mediated HER2 downregulation and tumor response in athymic
mice bearing MDA-MB-361 human breast cancer xenografts.
J Nucl Med 2009;50:1340–8, doi:10.2967/jnumed.109.062224.
18. Kramer-Marek G, Gijsen M, Kiesewetter DO, et al. Potential of
PET to predict the response to trastuzumab treatment in an
ErbB2-positive human xenograft tumor model. J Nucl Med 2012;
53:629–37, doi:10.2967/jnumed.111.096685.
19. Wong JY, Raubitschek A, Yamauchi D, et al. A pretherapy
biodistribution and dosimetry study of indium-111-radiolabeled
trastuzumab in patients with human epidermal growth factor receptor
2-overexpressing breast cancer. Cancer Biother Radiopharm 2010;25:
387–94, doi:10.1089/cbr.2010.0783.
6 Gaykema et al
